UNSPSC 51272305: Etomidate sulfate

This classification denotes an anesthetic agent with the molecular formula C14H16N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y26131IQZI, chemically known as 1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (r)- sulfate (1:1) but more generally known as etomidate sulfate, which bears US NIH Compound Identifier 3084993. European Medicines Agency schedules Etomidate sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02047MIG.

Most nations, for tariff and trade purposes, schedule etomidate sulfate under HS 29332990 and SITC 51573. As of Q4 2014, ETOMIDATE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)C1CNCN1[C@H](C)C2CCCCC2.OS(=O)(=O)O.

UNSPSC 51272305 Etomidate sulfate, a Commodity code, shows limited direct recent activity under its nominal scope; the few state and local opportunities tagged to this code involve broader pharmaceutical and medical supply procurement rather than etomidate specifically. State and local governments that do source under this code typically operate through health departments, emergency medical services programs, and public health agencies that stock injectable anesthetics and emergency medications. Recent solicitations reflect procurement patterns in which jurisdictions source pharmaceuticals through cooperative purchasing alliances, authorized wholesale distribution networks, and competitive bidding processes that bundle multiple drug products rather than sourcing etomidate in isolation.

Activity is sparse and geographically scattered. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems through quarterly deliveries to its Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs. The code appears to see limited standalone procurement volume; most activity occurs within multi-product pharmaceutical solicitations issued by state health agencies and county public health departments using cooperative purchasing vehicles.